Fourth Dimension Wealth LLC Decreases Stake in Insmed, Inc. (NASDAQ:INSM)

Fourth Dimension Wealth LLC decreased its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 59.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,622 shares of the biopharmaceutical company's stock after selling 2,399 shares during the period. Fourth Dimension Wealth LLC's holdings in Insmed were worth $124,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. grew its stake in shares of Insmed by 37.7% in the first quarter. Oppenheimer Asset Management Inc. now owns 19,935 shares of the biopharmaceutical company's stock worth $1,521,000 after purchasing an additional 5,453 shares during the last quarter. Whalen Wealth Management Inc. purchased a new stake in Insmed in the 1st quarter worth approximately $217,000. Avior Wealth Management LLC grew its position in shares of Insmed by 82.2% in the 1st quarter. Avior Wealth Management LLC now owns 4,151 shares of the biopharmaceutical company's stock worth $317,000 after buying an additional 1,873 shares during the last quarter. Sowell Financial Services LLC bought a new stake in shares of Insmed in the 1st quarter worth approximately $255,000. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Insmed by 16.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock valued at $288,000 after buying an additional 541 shares during the period.

Insider Activity

In related news, CEO William Lewis sold 6,830 shares of the company's stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the transaction, the chief executive officer now owns 233,924 shares in the company, valued at $16,412,107.84. The trade was a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 409 shares of Insmed stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $65.61, for a total transaction of $26,834.49. Following the completion of the transaction, the insider now directly owns 91,794 shares of the company's stock, valued at $6,022,604.34. This trade represents a 0.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 488,752 shares of company stock worth $43,199,826 over the last three months. 3.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on INSM. Bank of America raised their price target on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. The Goldman Sachs Group raised their target price on shares of Insmed from $100.00 to $112.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Wells Fargo & Company lifted their target price on shares of Insmed from $107.00 to $119.00 and gave the company an "overweight" rating in a research note on Wednesday, June 11th. Morgan Stanley boosted their price target on shares of Insmed from $90.00 to $102.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Insmed in a research note on Tuesday, June 10th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $106.80.

Insmed Price Performance

INSM stock opened at $99.49 on Friday. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86. The firm has a 50 day moving average price of $78.01 and a 200-day moving average price of $75.54. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $106.83. The firm has a market capitalization of $18.87 billion, a price-to-earnings ratio of -16.72 and a beta of 0.80.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The company had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same period last year, the business earned ($1.06) EPS. The firm's quarterly revenue was up 22.9% on a year-over-year basis. Equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.